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Abstract
Background: Allergic Rhinitis (AR) is a common disorder in Europe with Allergic Asthma (AA) as a frequent comorbidity.
Allergy immunotherapy (AIT) is the only causal therapy of AR and AA, and can be administered as subcutaneous
injections at the physician or as sublingual drops or tablets at home. The usual treatment duration is 3 years.
Objective: This study aimed to elicit patient preferences to identify the AIT administration mode preferred by patients.
Methods: A discrete-choice-experiment (DCE) was developed to determine how people weight different treatment
options using a paper-based questionnaire from June to September 2014, including 16 study centres. Main inclusion
criteria: >18 years, grass, birch and/or house dust mite AR with moderate to severe symptoms, AIT-naïve and
AIT-indicated. DCE-attributes were: Administration form, number and duration of physician visits, frequency of
life-threatening anaphylactic shocks, local side-effects and co-payments.
Results: Two-hundred thirty-nine subjects participated, resulting in analysable 1842 choices. All attributes were
significant predictors for the treatment-choice. Ranked by importance, the following first three attributes are most
preferred by patients:
1st Number and duration of physician visits:
Fewer visits with shorter duration preferred (0.658*)
2nd Frequency of life-threatening anaphylactic shocks:
Lower risk of shocks preferred (0.285*)
3rd Local side-effects:
Preference for rash/swelling on upper arm over itching/swelling under the tongue (0.210*)
(*coefficient-size represents relative importance of the attributes)
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Conclusion: The most important attribute is the number and duration of visits to a physician. A lower risk of
life-threatening anaphylactic shocks was ranked as the second whereas co-payments and administration form play a
limited role.
Keywords: Allergic rhinitis, Allergy immunotherapy, Discrete-choice-experiment, Patient preferences, Sublingual
immunotherapy-tablet
Abbreviations: AA, Allergic asthma; AIT, Allergy immunotherapy; AR, Allergic rhinitis; ARIA, Allergic rhinitis and its
impact on asthma; DCE, Discrete-choice-experiment; IQWiG, German Institute for Quality and Efficiency in Health Care;
N / n, Population; SCIT, Subcutaneous immunotherapy/Injections; SLIT, Sublingual immunotherapy; VAS, Visual
analogue scale
Background
Allergic rhinitis (AR) is a common disorder in Europe,
affecting more than one out of five adults and represent-
ing a considerable burden both on the individual patient
and the society [1, 2]. AR is associated with comorbidities
as well as long-term consequences frequently including
allergic asthma (AA). More than one third of allergy
patients are also diagnosed with asthma. In addition, AR
is associated with burdensome symptoms, a loss of
productivity as well as the impairment of daily activities
and quality of sleep [3, 4]. Accordingly, in subjects with AR,
the health-related quality of life is significantly affected [5].
Allergy immunotherapy (AIT) is a form of treatment
that induces a protective immune response and aims to
treat the underlying immunological cause of the
allergy. Besides of symptom relief, also long-term effi-
cacy and the prevention of other allergic diseases, such as
the development of asthma, are intended. AIT results in a
significant reduction of the symptom burden and medica-
tion need [6].
AIT can be administered by subcutaneous injections
(SCIT), followed 30 min monitoring for side effects, at
the physician’s office or as sublingual drops or tablets
(SLIT-drops or SLIT-tablets) at home [7, 8]. There are
products in both administration forms for which, after
3 years of continuous AIT, a sustained treatment effect
after treatment stop has been observed [8, 9]. Available
AIT not only differs regarding the administration form,
the therapy options also differ regarding the type of local
side-effects, the risk of a life-threatening anaphylactic
shock, co-payments and the number of necessary visits
to a physician [6, 10].
An increasing number of patient preference studies
are being conducted as measuring patient preferences is
a very important component to understand how health-
care in an indication may or should evolve in the future.
The aim of preference-based evaluation methods is to
assess and weight benefits, costs and risks of therapy
options with respect to the individual needs of patients.
Analysing the preferences of patients that are intended
for an AIT treatment can help to identify distinct
features of therapies that have a major influence on the
patient benefit. Those insights should be implemented
to provide an improved provision of healthcare. The
identification of product or service determinants that are
preferred by patients is therefore described to enable
improved compliance, optimised outcomes and can help
to guide drug development [11, 12]. In the current
German AIT-guideline that focuses on the management
of patients with AR and/or AA, the improvement of
compliance is defined as a major task of the future,
which is needed to ensure the therapy success and
causal efficacy of AIT [8].
Summarising, preference-based evaluation methods
help to determine suitable or optimised treatment strat-
egies. They enable the creation of a benefit basket which
offers a high fit to the individual needs of patients.
Basing medical care on the needs and preferences of
patients is also acknowledged to enhance the compli-
ance [12].
Accordingly, the aim of the current study was to elicit
patient preferences to identify the most important attri-
butes for patients being indicated for AIT and to determine
patient preferences in regard to central distinguishing
characteristics of the AIT administration forms SCIT and
SLIT-tablet. Therefore a discrete-choice-experiment (DCE)
was developed, which is a method that is increasingly used
and acknowledged to elicit patient preferences in health-
care research.
Methods
Theoretical background of DCEs
In health economics, patient preferences are increasingly
being elicited by using conjoint analyses, a method to
determine how subjects weight and assess different
characteristics (or attributes) of a health technology or
service in terms of their importance. Based on the
Demand Theory developed by Lancaster in 1966 [13],
the preference measurement applied in this approach
assumes that a therapy is compounded by one or more
different attributes (e.g. visit frequency or side-effects
etc.), which in sum represent a given product [12].
Damm et al. Health Economics Review  (2016) 6:32 Page 2 of 9
The discrete-choice approach is explicitly recommended
and acknowledged by regulatory institutions evaluating
methods for the measurement of patient preferences to
weight and rank single preferences [14]. Accordingly, the
present DCE study was developed in accordance with the
recommended methodological practice induced by the
German Institute for Quality and Efficiency in Health
Care, the IQWiG.
DCEs are a choice-based alternative of the conjoint
analysis (Random Utility Theory) [15]. In DCEs, product
choices are characterised by different attribute levels
(e.g. oral medication or injection). The choices are
mostly presented in pairwise different hypothetical
treatment options and study participants have to decide
for one of the options [16]. It is assumed that individuals
will opt for those health products/therapy alternatives that
promise a higher degree of satisfaction of individual
patient needs in regard of their properties [12]. Further
details on the method of DCE can be found e.g. in [17–19].
Study design
The study was approved by the ethics committee of
Hannover Medical School (votum number: 2149–2014),
participants were informed and informed consent was
obtained. The study population comprised patients meeting
the following inclusion criteria:
– Age: minimum of 18 years
– Fluent in German
– AR with moderate to severe symptoms according to
the ARIA guideline [7] for a minimum of 2 years
against at least one of the following allergens: grass
pollen, birch or house dust mite
– Indication for AIT
– No AIT in the history
Patient recruitment was performed Germany-wide by
16 allergy specialist offices in the ambulatory setting.
The patients were asked to complete a paper-based
questionnaire. The pilot phase was carried out in April
2014 with 21 AR patients to check the practicality, feasi-
bility and methodology of the questionnaire. The main
study was conducted between June and September 2014.
The questionnaire covered the four following main
areas:
1. General information about AIT (e.g. different types
of AIT, efficacy) and the DCE study format
2. The DCE for eliciting preferences
3. Additional questions evaluating the DCE
(5-point Likert scales formulated to probe the DCE
results within a mix of methods)
4. Questions on socio-demographic characteristics like
gender, age, education, employment status
Additionally, allergy specific questions (type of allergy,
severity of symptoms in terms of the ARIA criteria) were
answered by the respective study physician in a separate
form, to control for the medical inclusion criteria.
Establishment of relevant product attributes
DCEs are in general confined to the use of only a limited
number of attributes to ensure the feasibility for the par-
ticipants. To identify relevant attributes describing dif-
ferent administration forms of AIT, a review of existing
literature was conducted. Results were discussed within
an expert workshop with allergists working in the ambu-
latory and/or in-patient setting. Five attributes were fi-
nally identified to describe the constructed hypothetical
treatment options. Each of the attributes was defined by
two levels designated to clearly distinguish between
SCIT and SLIT-tablet treatment (see Table 1). The total
number and duration of necessary visits to a physician
was added to the choice set of attributes as that domain
was shown to be a relevant discriminating factor be-
tween SCIT and SLIT in an earlier study by Peter et al.
[10]. In addition, also Sondermann et al. identified the
time load of an AIT treatment as a central factor for the
Table 1 Attributes, Levels and descriptions included in the DCE
Attributes Characteristics (Levels) SCIT Characteristics (Levels) SLIT
Administration form An injection given every visit at the
physician’s office
A tablet taken every day at home
Total number and duration of necessary visits to a physician 24 times for 45 min over 3 years 12 times for 15 min over 3 years
Frequency of a life-threatening anaphylactic shock
(An anaphylactic shock is a sudden, serious, life threatening
allergic reaction)
1 in 10,000 patients 1 in 100,000 patients
Local side-effects
(Local side-effects occur in approximately half of the patients
during the first months of treatment)
Rash or swelling
sited at the upper arm
Itching or swelling under the tongue
Sum of co-payments for the whole treatment
(Co-payments are paid at the pharmacy when picking
up a prescription)
€60 over 3 years €120 over 3 years
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patient and for the success in regard to the therapy adher-
ence [20]. The frequency of a life-threatening anaphylactic
shock as well as the type of non-life-threatening local
side-effects was included to the attributes, since these are,
besides efficacy, the most common outcome parameters
used in clinical AIT trials [6] and in AIT therapy guide-
lines to evaluate and compare AIT therapies [8, 9]. The
total sum of co-payments is another characteristic to
distinguish AIT administration options. The included
levels of €60 versus €120 were calculated as average values
for filled prescriptions in the public pharmacy over the
whole treatment duration of 3 years.
As essential pre-condition, the efficacy between SCIT
and SLIT-tablets was appointed as being equal within
the conducted DCE, based on the required guideline
standards and a current meta-analysis comparing SCIT
and SLIT [21]. This fact was also explained to the partici-
pants in the questionnaire before constructed DCE-choice
sets were to be answered.
Selection of choice sets
Since it was not feasible to include all available attribute
combinations (25 = 32) in the questionnaire, a reduced
(or factorial) experimental design was used. For this
purpose, an orthogonal main effects plan designed by
Street et al. [22] was applied, which allows for a reliable
evaluation of preferences [23]. Based on the five AIT
attributes, eight hypothetical therapy choice sets were
generated. To receive optimal pairs, from which the
patient had to select one (immunotherapy A or B) the
profiles for the second option of the pair were created
by using the fold-over method. Thus, maximal dissimi-
larity between the two options was achieved. A question
including an opt-out option has also been included in
the Choice set. Table 2 shows one example of the resulting
choice sets.
Data analyses
In the current study, the calculation of coefficients was
performed by conducting a conditional logit model using
the maximum likelihood method being considered as
the most appropriate methodological approach. Due to
the binary attribute levels, a dummy coding was used.
Data entry, clean-up and analysis were performed with




A total of 273 participants completed the questionnaire.
34 of these patients did not meet the inclusion criteria
in full (age <18 years: n = 2; no AR: n = 10; AR, but with
only mild symptoms: n = 22) and had to be excluded from
the analysis, resulting in 239 included participants.
Table 3 shows socio-demographic and disease-specific
characteristics of the study participants. 58 % of the in-
cluded participants were female; most participants were
younger than 46 years (70 %) corresponding to a mean
age of 38 years. Nearly 60 % had a higher education
(university entrance diploma or university diploma).
Twenty-five percent of the participants had children
(<14 years) that also live in their household. A majority
(78 %) of the patients were currently employed, mainly
full-time (35–40 h per week). The data regarding the
types of allergy shows that a majority of participants
suffer from more than one allergy. The cohort seems to
offer an expected mix of patients with AR and/or AA
with a somewhat higher educational background
Table 2 Exemplary DCE choice set
Immunotherapy A Immunotherapy B
Administration form A tablet taken every day at home An injection given every visit at
physician’s office
Total number and duration of necessary
visits to a physician
24 times for 45 min over 3 years 12 times for 15 min over 3 years
Frequency of a life-threatening
anaphylactic shock
1 in 10,000 patients 1 in 100,000 patients
Local side-effects Itching or swelling under the tongue Rash or swelling sited at the
upper arm
Sum of co-payments for the
whole treatment
€120 over 3 years €60 over 3 years
Question 1:
Which of the two therapies would
you use?
❒A ❒B ❒None of them
Question 2:
Which of the two therapies do you
prefer even if you don’t use it?
❒A ❒B
(the displayed Immunotherapies A and B are just two of a number of hypothetical possibilities)
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compared with the general population, which is not un-
usual in studies of this type.
By using a Visual Analogue Scale (VAS) ranging from
0 (not at all burdensome) to 100 (extremely burden-
some), patients were asked to assess the severity of nasal
symptoms as well as symptoms affecting the eyes. Table 3
shows that a majority of patients rated their symptoms
in the top half of the scale (50–100). The results support
the diagnosis given by the study physicians, which means
that the cohort is representative of a population with
moderate to severe AR.
Complexity of questionnaire
To evaluate the DCE, the participants were asked to as-
sess the difficulty of the experiment on a 5-point Likert
scale ranging from “not at all difficult” to “very difficult”.
Most participants (84 %) stated that the questionnaire
was “not very”or “not at all” difficult. Only 8 % of the
participants assessed it as “somewhat” or “very” difficult.
This finding is important as it implies that participants
were able to understand the task and were able to ex-
press their preferences rather than introducing bias by
an inability to understand the questionnaire.
Preferences in the DCE
One-thousand eight hundred forty-two (or 96 %) out of
maximum 1912 choices (239 patients × 8 decisions)
were included in the model. 70 choices (4 %) were not
included due to missing data, as some of the respon-
dents did not rate all pairs. In nearly 90 % of all cases,
the participants would use one of the given treatment
options and therefore did not select the provided opt-
out option.
First of all, the results show that all attributes included
in the model had a significant impact on the choices
made by the participants (see Table 4). The model itself
is highly significant meaning that the null hypothesis of
no relationship between choice and the attributes can be
rejected. Hence, all attributes preferences are significant
predictors for the choice of a treatment, but with a dif-
ferent magnitude.
Patient preferences ranked by importance
The levels of the coefficients explain the relative import-
ance of the various attributes. The most important attri-
bute for the decision of the participants is the “Total
number and duration of necessary visits to a physician”:
Patients preferred less and shorter visits with the highest
preference or coefficient value (−0.65838). Participants
were significantly less likely to choose an AIT with “24
times for 45 min over 3 years” compared with “12 times
for 15 min over 3 years”. The coefficient is negative as
“24 times for 45 min over 3 years” was selected as the
reference categories and participants decided to opt
Table 3 Socio-demographic and disease characteristics of study
participants
Gender Number Percentage
Valid 239 100 %
Male 101 42 %
Female 138 58 %
Age (yrs.)
Valid 239 100 %
18–30 88 37 %
31–45 77 32 %
46–60 53 22 %
>60 21 9 %
Education
Valid 233 100 %
Lower or general education 96 41 %
Higher education 137 59 %
Children <14 years in household
Valid 229 100 %
No 171 75 %
Yes 58 25 %
Currently employed
Valid 234 100 %
No 51 22 %
Yes 183 78 %
Full-time 138 75 %
Part-time 36 20 %
Other 6 3 %
Missing 3 2 %
Type of allergy
Valid 239 100 %
Birch (of those birch only) 126 (37) 53 % (29 %)
Grass pollen (of those grass pollen only) 158 (50) 66 % (32 %)
House dust mite (of those house
dust mite only)
91 (33) 38 % (36 %)
Severity of nasal symptoms (assessed by patient)
Valid 229 100 %
VAS 0–49 30 13 %
VAS 50–100 199 87 %
VAS average 72
Severity of symptoms affecting the eyes (assessed by patient)
Valid 227 100 %
VAS 0–49 75 33 %
VAS 50–100 152 67 %
VAS average 57
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against this level of the attribute “Total number and
duration of necessary visits to a physician”.
The second and third most important attributes in the
ranking are the “Frequency of a life-threatening anaphyl-
actic shock” (coefficient: −0.28455) and the type of
“Local side-effects” (coefficient: 0.21045). Participants
were less likely to choose an AIT with a higher fre-
quency of an anaphylactic shock (1 in 10,000) compared
with a lower frequency (1 in 100,000) and preferred an
AIT that causes “Rash or swelling sited at the upper
arm” compared with “Itching or swelling under the
tongue”.
The first three attributes had the highest magnitude in
their effects. Less important attributes have been the co-
payments and administration form. Participants pre-
ferred an AIT with lower over higher co-payments. This
attribute, however, had the second lowest importance
(0.12593) and is less significant (p = 0.0123) compared
with the above mentioned.
The attribute “Administration form” achieved the lowest
coefficient and lowest significance (0.10769; p = 0.0306)
and is of less importance from a patient preference per-
spective compared with the other attributes. As men-
tioned, 5-point Likert scale questions were formulated to
probe the DCE results within a mix of methods. The
Likert scale results showed coherence for all prefer-
ences except for the administration form, where more
patients preferred a tablet over an injection with 49 %
preferring the tablet, 32 % an injection and 18 % being
neutral.
Figure 1 shows that the allocated importance, looking
at the overall magnitude of the preference expression,
was given to those attributes that are in favour of the
SLIT-tablet.
Table 4 Results of the DCE model (Ranked by importance)
Attributes Coefficient Standard error ChiSqa Pr > ChiSq (significance)
Total number and duration of necessary visits to a physician
24 times for 45 min over 3 years −.65838 .05034 171.0415 ***(<.0001)
12 times for 15 min over 3 years 0
Frequency of a life-threatening anaphylactic shock
1 in 10,000 patients −.28455 .05032 31.9785 ***(<.0001)
1 in 100,000 patients 0
Local side-effects
Rush or swelling sited at the upper arm .21045 .05032 17.4935 ***(<.0001)
Itching or swelling under the tongue 0
Sum of co-payments for the whole treatment
60 Euros over 3 years .12593 .05031 6.2647 **(.0123)
120 Euros over 3 years 0
Administration form
Injection .10769 0.04980 4.6771 *(.0306)
Tablet 0
Significance levels denoted by
*** Highly significant (p ≤ 0.001); ** Very significant (p ≤ 0.01); * Significant (p ≤ 0.05)
a chi-square
Fig. 1 Overview of preference elicitations
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Table 4 shows the results (incl. coefficients and sig-
nificance levels) of all attributes included in the DCE
model.
Discussion
Different estimation methods of DCE data can be found
in the literature [17]. In most cases, probit or logit esti-
mations are used. For the current study, the conditional
logit model has been evaluated as the best methodo-
logical approach. By the use of the DCE method, study
participants were implicitly forced to weight different
product attributes simultaneously. Hereby, the weak-
nesses of single-attributive approaches (e.g. Likert scales)
with ceiling effects and “all-is-important” results, when
asking individuals single disconnected questions, were
avoided [24]. Accordingly, the discrete-choice method is
explicitly recommended by regulatory institutions evalu-
ating health technologies for the measurement of patient
preferences for purposes of weighing and ranking of
single preferences [14].
The DCE results of the study showed that allergy
patients suffering from AR symptoms have the strongest
preference for AIT with less and shorter visits to a phys-
ician. Compared with all other attributes included in the
DCE, the Total number and duration of necessary visits
to a physician had the highest impact on the AIT choice.
The effect size of this attribute was rated by the parti-
cipants as approximately six times as important as the
attribute with the lowest preference. This preference for
shorter and fewer visits to a physician might be a reason
why the demand for AIT products with only few dosages
is growing, even if the scientific evidence for clinical effi-
cacy is poor or even missing in most of these products
[8]. Looking at the evidence level in terms of efficacy of
the existing products in the market, the SLIT-tablet is
the only administration form which fulfils both condi-
tions—a low number and duration of visits to a phys-
ician [10] and a high level of evidence for efficacy at the
same time [8]. This could also be intuitively assumed a
reason why especially patients who are (highly) engaged
in private and/or working life might be a subpopulation
of patients for which an AIT therapy with the SLIT-
tablet could fit best.
In AIT, local reactions at the application site as well as
systemic reactions can occur. SLIT in general has a
lower risk for potentially life-threatening systemic reac-
tions than SCIT, even if SCIT is also considered as a
well-tolerated treatment option for allergic diseases in
an allergist’s setting [7, 8]. Further, the attribute with the
second highest impact on AIT treatment choices was
the frequency of a life-threatening anaphylactic shock
and the effect size can be rated as approximately half as
important as the first attribute. The DCE results show
that the included patients had a stable preference for an
AIT with a lower probability of experiencing an anaphyl-
actic shock, which is an intuitive finding. But the rank-
ing compared with the other attributes shows that the
risk profile of a therapy alternative is of a relatively high
importance from the patient perspective. The type of
local side-effects was another important AIT attribute.
Study participants preferred a “Rash or swelling sited at
the upper arm” over “Itching or swelling under the
tongue” in the DCE. One reason for this result might be
that patients with respiratory allergy are especially sensi-
tive to effects or restrictions in the mouth. Overall, it
can be said, also in accordance with the current German
AIT guideline, that the SLIT-tablet risk profile is described
to be superior compared with the SCIT risk profile [8].
In the German healthcare system, co-payments by the
patients for their medication are required. These co-
payments are related to the costs of the medications
[25]. The co-payments had a minor and slightly less sig-
nificant impact on the AIT treatment choices in the
DCE. As expected, the participants preferred lower com-
pared with higher co-payments, but the relative prefer-
ence importance of this attribute compared with the
other attributes is only small. This might be due to the
fact that the participants were willing to pay a higher
amount of money for a therapy that matches their pref-
erences. An additional factor might also be that the aver-
age educational background was higher than in the
normal population. And as a higher educational back-
ground is known to be associated with a higher income
[26], this correlation might also lead to a lower sensitiv-
ity in regard of costs. However, further investigation on
willingness to pay by study subjects under different sce-
narios might offer a deeper understanding of influencing
factors in this respect.
The attribute administration form achieved the lowest
coefficient, and is of relative less importance from a
patient preference perspective. Therefore, it can be con-
cluded, that the attributes frequency of visits and life-
threatening anaphylactic shocks were the most import-
ant from a patient perspective. Those attributes are
clearly expressing the preference in favour of the SLIT-
tablet, and when asking patients directly in context of a
Likert scale, the results show that the administration
form is of major importance to them, and that they pre-
fer a tablet over injections.
Some limitations of the study need to be addressed. A
general critique concerning the DCE method (and all
other stated preference methods) is that it may not
predict real behaviours and choices. However, especially
the DCE method emulates consumer behaviour and well-
known decision situations [14].
DCEs can only elicit the relative relevance of the attri-
butes that were included in advance. As already stated,
the efficacy between SCIT and SLIT-tablet AIT was set
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equal for this study in the adult therapy setting, as no
generalisable distinction between administration forms is
indicated [8, 21]. Accordingly, there is no signal from
the current study data on the relative importance of the
efficacy as an attribute of AIT compared with the other
included attributes. As AIT is defined as the only causal
therapy of allergic diseases, the AIT-efficacy level, in-
cluding long-term effects or the prevention of new
sensitisations, differs from plain symptomatic treatment.
In this sense, the choice of AIT-products should always
be based on a decision for the product with the highest
documented evidence level to ensure the best possible
treatment effect. If two or more different evidence-based
treatment options are available, patient preferences
should be taken into account.
Conclusion
As a first major insight of the conducted study, it can be
ascertained that there are preferences for existing AIT
administration forms in place. Patient preferences play
an increasing role in healthcare environment and shall
be taken into account where different comparable
treatment options are available. Under the precondition
of the study that products do have a comparable efficacy
and evidence level, the major preference was assigned to
the total number and duration of necessary visits to a
physician. Co-payments and the administration of a
product seem to play a comparably limited role. Looking
at currently available AIT treatment options on the
market, it can be concluded that SLIT-tablets seems to
be the therapy option which presently matches best the
preferences of patients considering the efficacy and
evidence of available treatment options.
Key messages
 The study ascertained that there are preferences
for existing AIT administration forms in place.
 The most important attribute is the number and
duration of visits to a physician, whereby fewer
visits with shorter duration were preferred.
 Patient preferences play an increasing role in
healthcare environment and shall be taken into
account where different comparable treatment
options are available.
Capsule summary
Patient preferences in Allergy Immunotherapy were
ascertained by a discrete-choice-experiment, which is
increasingly used and acknowledged in health care re-
search. Elicited preferences shall be considered in
clinical practice where different comparable treatment
options are available.
Acknowledgements
The study was funded by ALK-Abelló, Hørsholm, Denmark.
Authors’ contribution
KD and JV have contributed equally as the main authors of the study. KD
and TM have contributed to the study design, study coordination, data
collection and statistical analysis, the analysis of results and the writing of the
manuscript. JV, NT-P and IT have contributed to the study design, project
management, the analysis of results as well as the writing of the manuscript.
EW, NS-H and TW have contributed to the study design and the analysis of
results. KB has contributed to the data collection and statistical analysis.
AH and J-PA have contributed to the study design and particularly in the
questionnaire development from the perspective of practicing allergologists.
All authors reviewed the manuscript.
Competing interests
The study was funded by ALK-Abelló. Janina Volk, Thomas Winkler, Ivonne
Thiessen and Eike Wüstenberg are employed by ALK-Abelló Arzneimittel
GmbH, Hamburg, Germany. Ninette Troensegaard-Petersen and Niels
Serup-Hansen are employed by ALK-Abelló, Hørsholm, Denmark. Kathrin
Damm, Kathrin Borchert and Thomas Mittendorf received unrestricted
funding for the conduct of the study. Andreas Horn has participated in
ALK Advisory Boards and ALK Clinical Trials and functioned as a speaker.
Jean-Pierre Allam received research grant support and speaker fees from
ALK-Abelló.
Author details
1Center for Health Economics Research Hannover (CHERH), Leibniz University
Hannover, Hannover, Germany. 2ALK-Abelló Arzneimittel GmbH, Griegstraße 75,
Haus 25, D-22763 Hamburg, Germany. 3ENT Practice am Neckar Dres. Zeuner, Horn &
Vasvari, Heidelberg, Germany. 4Department of Dermatology and Allergy, University of
Bonn, Bonn, Germany. 5ALK-Abelló, Hørsholm, Denmark. 6Xcenda GmbH, Hannover,
Germany. 7Department for Otorhinolaryngology, Medical Faculty Dresden University,
Dresden, Germany.
Received: 22 April 2016 Accepted: 22 July 2016
References
1. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis
in Europe. Eur Respir J. 2004;24(5):758–64.
2. Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop Group, World Health
Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol.
2001;108 Suppl 5:147–334.
3. Crystal-Peters J, Crown WH, Goetzel RZ, Schutt DC. The cost of productivity
losses associated with allergic rhinitis. Am J Manag Care. 2000;6:373–8.
4. Spector SL. Overview of comorbid associations of allergic rhinitis.
J Allergy Clin Immunol. 1997;99:773–80.
5. Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. Quality of life in
allergic rhinitis and asthma. A population-based study of young adults.
Am J Respir Crit Care Med. 2000;162:1391–6.
6. Hagen A, Gorenoi V, Schönermark MP. Specific immunotherapy (SIT) in the
treatment of allergic rhinitis. GMS Health Technol Assess. 2010;16(6):Doc01.
7. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ. et al. Allergic
Rhinitis and its Impact on Asthma (ARIA) 2008 Update. Allergy. 2008;
63(Suppl. 86): 8–160.
8. Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C. et al. Guideline on allergen-
specific immunotherapy in
IgE-mediated allergic diseases. Allergo J Int. 2014;23:282–319.
9. Kleine-Tebbe J, Bufe A, Ebner C, Eigenmann P, Friedrichs F, et al.
Specific Immunotherpy (hyposensitization) for
IgE-mediated allergic diseases—Guideline of the German Society of Allergy
and Clinical Immunology. Allergologie. 2010;33(1):3–34.
10. Peter RU, Weimer M, Goertzen W, Holdt C, Schreder CH. Zeitaufwand der
Hyposensibilisierungstherapie mit subkutaner und sublingualer Applikation
unter Praxisbedingungen. Allergologie. 2012;35(3):5–8.
11. Mühlbacher A, Bethge S, Tockhorn A. Präferenzmessung im
Gesundheitswesen: Grundlagen von Discrete-Choice-Experimenten
[Measuring Preferences in Healthcare: Introduction to Discrete-Choice
Experiments]. Gesundheitsökonomie & Qualitätsmanagement; Stuttgart.
2013;4:159–72.
Damm et al. Health Economics Review  (2016) 6:32 Page 8 of 9
12. Mühlbacher AC, Bethge S, Ekert S, Tockhorn A, Nübling M. Der Wert von
Innovationen im Gesundheitswesen: Spielen die Patientenpräferenzen eine
Rolle. RPG. 2008;14(2):53–62.
13. Lancaster KJ. A new approach to consumer theory. J Polit Econ.
1966;74(2):132–57.
14. German Institute for Quality and Efficiency in Health Care (IQWiG).




15. Mcfadden D. Conditional Logit Analysis of Qualitative Choice Behavior.
In: Zarembka P, editor. Frontiers in Econometrics. Academic Press: New York;
1974. p. 105–42.
16. Ben-Akiva ME, Lerman SR. Discrete choice analysis: theory and application
to travel demand. Cambridge: MIT Press; 1985.
17. de Bekker Grob EW, Ryan M, Gerard K. Discrete choice experiments in
health economics: a review of the literature. Health Econ. 2010;21(2):145–72.
18. Clark MD, Determann D, Petrou S, Moro D, de Bekker-Grob EW. Discrete
choice experiments in health economics: a review of the literature.
Pharmacoeconomics. 2014;32(9):883–902.
19. Louviere J, Hensher D, Swait J. Stated choice methods: analysis and
applications. Cambridge Univ. Cambridge: Cambridge Univ. Press; 2000.
20. Sondermann N, Shah-Hosseini K, Henkel K, Schwalfenberg A, Mösges R.
Erfolgsfaktoren der Adherence bei Hyposensibilisierung. Allergologie.
2011;34(9):441–6.
21. Nelson H, Cartier S, Allen-Ramey F, Lawton S, Calderon MA. Network
Meta-analysis Shows Commercialized Subcutaneous and Sublingual Grass
Products Have Comparable Efficacy. J Allergy Clin Immunol Pract.
2015;3(2):256–66.
22. Street D, Burgess L, Louviere JJ. Quick and easy choice sets: Constructing
optimal and nearly optimal stated choice experiments. Int J Res Mark.
2005;22(4):459–70.
23. Street DJ, Burgess L. The construction of optimal stated choice experiments,
theory and methods. New Jersey: Wiley; 2007.
24. Mühlbacher AC, Lincke HJ, Nübling M. Evaluating patients’ preferences for
multiple myeloma therapy, a Discrete-Choice-Experiment. GMS Psychosoc
Med. 2008;5:Doc10.
25. Social Code Book V. http://www.sozialgesetzbuch-sgb.de/sgbv/61.html.
Accessed 15 Aug 2014.
26. Autorengruppe Bildungsberichterstattung. Bildung in Deutschland
2012—Ein indikatorengestützter Bericht mit einer Analyse zur kulturellen
Bildung im Lebenslauf; W. Bielefeld: Bertelsmann Verlag; 2012.
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Damm et al. Health Economics Review  (2016) 6:32 Page 9 of 9
